Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung

Next Previous
X
Search
Trial Profile

A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 02 Feb 2023 Status changed from recruiting to completed.
    • 31 Jan 2021 Results of an exploratory analyses of response and survival in patients classified by EGFR mutation types presented at the 2020 World Conference on Lung Cancer
    • 31 Jan 2021 Results (n=105; data cut off date Aug 15, 2019) assessing efficacy, safety and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous non-small cell lung cancer, presented at the 2020 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top